SAN DIEGO--20 Feb--PRNewswire-AsiaNet/InfoQuest
A new analysis from the JUPITER study presented today at the International Stroke Conference (ISC) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk
factors. This data adds to the primary analysis of the JUPITER study which demonstrated that CRESTOR? (rosuvastatin calcium) 20mg significantly reduced the risk of stroke by nearly half (48%; p=0.002), compared to placebo among men and women with elevated hsCRP but low to normal cholesterol levels.
"Stroke is the third most common cause of death in developed countries. Globally around 15 million people have a stroke every year and of these about 5 million die and another 5 million are left permanently
disabled, with conditions such as paralysis, cognitive deficits, speech problems, emotional difficulties, daily living problems and pain.
Rosuvastatin has previously shown that it can slow the progression of atherosclerosis, which is a major underlying cause of stroke", said Michael Cressman, Director of Clinical Research for CRESTOR. "This analysis of the JUPITER data evaluated rosuvastatin 20 mg across a number of subgroups with notable benefits in higher risk patients including those older than 70 years, cigarette smokers, hypertensives, those with an elevated Framingham risk score, and those with a high-sensitivity C-reactive protein level at or above 5 mg/L at baseline."
There was no increase in the risk of hemorrhagic stroke (P=0.44 vs placebo) in patients treated with rosuvastatin. Rosuvastatin 20 mg was well tolerated in nearly 9,000 patients during the course of the JUPITER
study.
Initial results from JUPITER, originally presented in November 2008 at the American Heart Association's Annual Scientific Sessions, and published by the New England Journal of Medicine, showed rosuvastatin 20mg
significantly reduced major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 44 % compared to placebo
(p